Immunotherapy for prostate cancer: walk, don't run.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

26 citing papers in PubMed, 43 citations in OpenAlex.

1. Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial.Cancer immunology, immunotherapy : CII · 2020
   Trial
2. Breaking barriers in prostate cancer: the mRNA vaccine breakthrough and what comes next.NPJ vaccines · 2026
   Review
3. Prostate tumor immune microenvironment changes following immunotherapy shared by patients who developed anti-tumor response or immune-related adverse events.Oncoimmunology · 2025
   Article
4. Targeted and immunotherapeutic strategies for castration-resistant prostate cancer: emerging strategies, challenges, and future directions.Frontiers in immunology · 2025
   Review
5. Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches.Cancer drug resistance (Alhambra, Calif.) · 2025
   Review
6. Emerging Cancer Immunotherapies: Cutting-Edge Advances and Innovations in Development.Medical sciences (Basel, Switzerland) · 2024
   Review
7. Cancer vaccines in the clinic.Bioengineering & translational medicine · 2024
   Review
8. Vaccines as treatments for prostate cancer.Nature reviews. Urology · 2023
   Review
9. A Perspective of Immunotherapy for Prostate Cancer.Cancers · 2016
   Review
10. Nanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy.Small (Weinheim an der Bergstrasse, Germany) · 2015
    Review
11. Immunotherapy in prostate cancer: review of the current evidence.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2015
    Review
12. Beyond the Immune Suppression: The Immunotherapy in Prostate Cancer.BioMed research international · 2015
    Review
13. The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014.Journal of translational medicine · 2014
    Review
14. Prostate cancer vaccines in combination with additional treatment modalities.Immunologic research · 2014
    Review
15. From bench to bedside: immunotherapy for prostate cancer.BioMed research international · 2014
    Review
16. Prostate cancer vaccines: Update on clinical development.Oncoimmunology · 2013
    Article
17. Proposed mechanisms of action for prostate cancer vaccines.Nature reviews. Urology · 2013
    Review
18. Don't run before you can walk.Nature reviews. Urology · 2012
    Article
19. Interleukin-6: a potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in castration-resistant prostate cancer.Urology · 2011
    Article
20. Cancer immunotherapy: sipuleucel-T and beyond.Pharmacotherapy · 2011
    Review

Corrections and comments

• Comment on
  Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer.2009

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as